Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact historically high in both 2020 and 2021. The scope of the problem. She has been vice resident, European Marketing and Thought Leadership in IQVIA for 12 years.
Let's personalize your content